Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only mechanism-level statements are supported by the provided label excerpt. Multiple claims about discounted treatment, PAP/copay/discount cards, and eligibility criteria (age, diagnoses, income, insurance, prescription requirement) are not supported by any provided FDA-approved prescribing information sections.
Category Scores
Accurate Statements
Yervoy is an immunotherapy.
12.1 Mechanism of Action (ipilimumab as CTLA-4 blocking monoclonal antibody augmenting anti-tumor immune response)
Yervoy works by boosting the body's immune system to fight cancer cells.
12.1 Mechanism of Action (augment T-cell activation/proliferation and may contribute to anti-tumor immune response)
Yervoy (ipilimumab) is a medication used to treat certain types of cancer.
12.1 Mechanism of Action (anti-tumor immune response; specific indications not provided in excerpts)
Unsupported Statements
Yervoy is used to treat melanoma.
No indication details were provided in the supplied label excerpts (1 INDICATIONS AND USAGE not provided).
Yervoy is used to treat lung cancer.
No indication details were provided in the supplied label excerpts.
Yervoy is used to treat kidney cancer.
No indication details were provided in the supplied label excerpts.
Discounted Yervoy treatment refers to the availability of Yervoy at a reduced cost for patients who meet certain eligibility criteria.
No label content provided addressing discounts, cost assistance, or eligibility criteria.
Discounted Yervoy treatment can be achieved through patient assistance programs, copay cards, and discount cards.
No label content provided addressing patient assistance, copay cards, or discount cards.
Patients must be at least 18 years old to receive Yervoy treatment (per the stated eligibility criteria).
No label content provided addressing program eligibility age requirements.
Patients must have a confirmed diagnosis of melanoma, lung cancer, or kidney cancer to qualify for discounted Yervoy treatment (per the stated eligibility criteria).
No label content provided addressing discounted-treatment eligibility criteria.
Patients must have a household income at or below 500% of the federal poverty level to qualify for discounted Yervoy treatment (per the stated eligibility criteria).
No label content provided addressing income thresholds for discount programs.
Patients must have insurance that covers Yervoy treatment to qualify for discounted Yervoy treatment (per the stated eligibility criteria).
No label content provided addressing insurance coverage requirements for discount programs.
Patients must have a prescription from a healthcare provider for Yervoy treatment to qualify for discounted Yervoy treatment (per the stated eligibility criteria).
No label content provided addressing prescription requirements for discount programs.
The manufacturer offers a patient assistance program (PAP) that provides free or discounted Yervoy treatment to eligible patients.
No label content provided describing manufacturer PAP offerings or free/discounted treatment terms.
A copay card provides a discount on out-of-pocket costs for Yervoy treatment.
No label content provided describing copay cards or out-of-pocket discounting.
A discount card provides a discount on the cost of Yervoy treatment.
No label content provided describing discount cards or cost reductions.
The patient assistance program (PAP) offered by the manufacturer provides free or discounted Yervoy treatment to eligible patients (as part of the listed discounted treatment programs).
No label content provided describing PAP terms or eligibility.
Contradictions
Important Omissions
Specific FDA-approved indications, dosage and administration, contraindications, warnings/precautions, drug interactions, and safety/monitoring details were not assessed because those label sections were not provided in the input.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims about access/eligibility (age, diagnoses, income, insurance, PAP/copay/discount cards) could mislead patients into believing discounted access is guaranteed based on stated criteria, while the provided FDA label excerpts contain no such information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Discount/access program descriptions and eligibility criteria are not supported by the provided FDA-approved prescribing information excerpts.
Suggested Improvement
Remove or rephrase discount/PAP/copay/discount-card and eligibility-threshold claims unless supported by the provided FDA label text; limit label-supported statements to the provided mechanism-level information.